delivering both single-field uniform dose and multiple-field intensity modulated proton therapy without the need for compensators or 
| ME TH ODS AND MATERIALS

2.A | Proteus â ONE overview
The IBA Proteus â ONE features an isochronous cyclotron, 220°par-tial-rotation compact gantry, scanning beam delivery nozzle, image guidance system with cone-beam CT and stereoscopic imaging capabilities, and a 6D robotic couch. Continuous dynamic spot scanning of the cyclotron-generated proton beam, coupled with rapid adjustment of beam energy, is used to treat three dimensional target volumes. Discrete dose deposition layers within a target, ranging from surface to 32-cm water equivalent thickness (WET), are achieved via adjustment of beam energy by a degrader and energy selection system (ESS) located between the cyclotron and PBS delivery nozzle.
Within each layer, scanning magnets direct discrete beamlets (spots)
along the x-and y-directions yielding a maximum proton field size of 20 9 24 cm in x-and y-directions at isocenter. Although IBA Proteus â ONE hardware produces and supplies the proton beam, additional equipment from both IBA and other vendors is necessary to achieve patient treatment delivery. A third-party TPS computes required layer energies, along with spot locations and weights, based on patient morphology for a set of user-specified beam (gantry) and couch angles. These patient-specific plan parameters, along with reference image datasets, are then transferred to a third-party OIS, which is also used to transfer both plans and image datasets to IBA's adaPTdeliver TM console system and adaPTinsight TM imaging system software, respectively, for treatment delivery as shown in Fig. 1 .
Accurate, seamless integration between these disparate systems is a crucial piece of the Proteus â ONE system. A series of simple spot positioning tests were also performed to verify spot placement accuracy. For the clinical range of beam energies, spots were placed AE5 and AE10 cm from the origin along the xaxis and AE6 and AE12 cm from the origin along the y-axis, and measured using the Lynx to quantitate the distances between the spots.
2.A.1 | Accelerator
This process was then repeated with spots placed along the diagonal.
2.B.2 | Absolute dose calibration
For passive scattering proton therapy systems, the relationship between absolute dose and monitor units can be established by the IAEA TRS398 protocol. 9 However, TRS398 does not adequately cover the dosimetry of PBS systems. . MU linearity of the nozzle's ionization chambers was also verified by scaling the plan's MUs to deliver 0.6, 0.8, 2, and 5 times the original dose.
2.B.3 | Variable virtual SAD (VSAD) measurement
The unique orientation of the scanning and bending magnets of the fit of the measured data was adopted to approximate its effect in the TPS. Phantom treatment plans were generated at clinically relevant treatment depths for various sites (e.g., prostate, whole pelvis, and cranium). Calculated dose distributions with and without VSAD consideration were compared for each plan.
2.C | TPS commissioning 2.C.1 | Raystation beam modeling
Beam modeling for the TPS required in-air spot profiles, integrated depth doses (IDD), and absolute dose measured at a depth between 1 cm and one-half of the Bragg peak maximum. While RaySearch recommends these measurements be taken at a depth equal to the PIDIKITI ET AL.
| 97 midpoint of this range, for simplicity, and with input from RaySearch, we performed all absolute dose measurements at a depth of 2 cm from the water surface for each mono-energetic beam. Beam data obtained with the range shifter in place was not required by RayStation as its effect is modeled within the dose engine. All necessary beam data were supplied to RaySearch Laboratories who then generated the final beam model, the details of which are beyond the scope of this paper.
2.C.2 | CT-to-density curve determination
Our clinic utilizes a Phillips Brilliance Big Bore 16-slice CT scanner for patient simulation. Using Gammex 467 tissue characterization plugs inside acrylic phantoms, we studied various CT acquisition settings and phantom sizes to establish imaging protocols and create a CT-to-density table from which the TPS estimates relative stopping power ratios for proton beam dose calculations. 5, 13, 14 These protocols were tested in the TPS by comparing the mass densities determined by the protocols in patient CT datasets against reference ICRU 49 data for known human tissues. 5 Accurate dose calculation in proton therapy depends on proton relative stopping power ratios. RayStation uses an internal mass density to stopping power conversion during dose calculation. Individual CT voxels are assigned a known biological material based on mass density. The stopping power is then calculated on the fly using the density of the voxel, the properties of the known material (e.g., mean excitation potential and elemental composition) and the Bethe-Bloch equation. A stoichiometric calibration was also independently performed by an external proton physicist to verify stopping powers calculated by RayStation.
2.C.3 | TPS validation
Measurement of spot profiles in solid water, depth doses for inversely optimized plans, lateral dose profiles, dose uniformity, absolute dose, and patient treatment field specific QA in homogenous phan- 
2.D.2 | Stereoscopic system characterization
Of primary concern during stereoscopic system characterization were both geometric accuracy and geometric integrity between the proton beam axis and stereoscopic imaging system axis. Isocentricity was also verified with the XRV100 scintillator (Logo System Intl, CA, USA), 7 which works on the principle of a hodoscope and can measure beam isocenter based on particle trajectory through the surface of a scintillator cone. The XRV100 was imaged with the CT scanner to create a reference image set, which was then transferred to adaPTinsight TM . The XRV100 was aligned in the treatment room by iteratively performing stereoscopic imaging and registration until residual corrections vectors were minimal. Isocentricity was then confirmed by exposing the XRV100 to single spot pristine beams from multiple gantry angles for a range of energies.
2.D.3 | Gantry mounted imaging system
The confirmation of radiation isocenter and stereoscopic imaging isocenter collinearity provided the ability to verify the gantrymounted imaging system (kV-kV orthogonal radiographs and conebeam CT) against the stereoscopic imaging system. A cube phantom with a central BB marker was first aligned to isocenter using stereoscopic oblique radiographs. Orthogonal kV-kV radiographs and both clockwise (CW) and counter clockwise (CCW) CBCTs of the cube phantom were then obtained and their respective registration shifts evaluated to confirm isocenter agreement between the stereoscopic and gantry-mounted imaging systems.
| RESULTS
3.A | Beam characterization
IDD measurements with the Bragg peak chamber for energies of 70-226.7 MeV in increments of 5 MeV are shown in Fig. 3 . Data T A B L E 1 Measured (Zebra) and expected R 90 for several pristine beams. are normalized to 100% at maximum dose. The range is defined by 90% on the distal edge of the Bragg peak. Table 1 
3.B | Absolute dose calibration
Using the TRS398 protocol 9 and measurement of dose at the middle of the SOBP with depth of 15 g/cm
À2
, the ratio of measured dose to TPS dose was found to be within AE0.5% for measurements inside the TPS-calculated volume both on and off central axis. Twenty measurements performed throughout the field at various depths confirmed TPS-predicted doses. Measured dose in the center of the volume at isocenter as compared to TPS calculation was within 0.2%. Additional plans and absolute dose measurements were performed as part of the TPS validation as described in Section 3.D.
3.C | CT-to-density table determination
Five patients (three pelvis and two prostate) were scanned and evaluated for adipose, muscle, and cortical bone physical density data as compared to the ICRU 49 protocol. 5 These density comparison results are summarized in Table 2 five patients mentioned previously and are presented in Table 2 .
RLSP comparisons for the Gammex tissue characterization plugs are presented in Table 3 .
3.D | TPS validation
TPS-calculated spot profiles were compared against measured data for a wide variety of clinical scenarios. Using the Lynx device, a total of 57 sets of measurements were obtained at various depths in solid water and proton ranges (energies), with and without the range shifter. Each measurement consisted of a layer containing 17 spots placed throughout the treatable field size (20 9 24 cm).
Relative gamma analyses between measured and TPS spot profiles were all greater than 95% passing with 3%/3 mm dose/distance agreement criteria. Measured and TPS spot sigmas all agreed within 0.5 mm for both x and y directions.
The distance-to-agreement (DTA) between TPS-calculated and Zebra-calculated ranges (R 90 ) was within 0.7 mm for all measured Pristine Bragg peaks. The SOBP plateau region is defined as that between the 50% point distally and the 98% proximally reduced by two distal fall-off widths (80%-20%) on each side. A comparison between measured and TPS-calculated point doses at various depths as a function of the air gap between the range shifter and phantom is given in Fig. 8 . A disagreement of approximately 6% (dose overestimation by TPS) was observed for a completely retracted range shifter at a proximal measurement depth of 1.5 cm. Relative depth dose comparisons for these test plans, normalized to the maximum SOBP dose, were also compared via Zebra TM measurements as shown in Fig. 9 . The results yield a less than 1 mm difference at the distal 90% edge in all cases. However, as observed with absolute dose discussed above, measured relative depth dose profiles are lower than their TPS-calculated counterparts on the proximal edge when there is a large air gap. The reason for this disagreement will be discussed in Section 4.
Final dose validation results from our IROC anthropomorphic phantom irradiations are given in Table 4 . All measurements met their respective IROC passing criteria.
3.E | Variable virtual SAD (VSAD) measurement
Evaluation of Lynx measurements indicated that the VSAD ranged A workflow limitation of the current IBA Proteus â ONE system is that patient setup images are not managed by the OIS for acquisition of either "Setup" or "Port" films before beam delivery. Instead, they are managed by the adaPTinsight TM application, restricting the ability of both the physicist and physician to perform remote review of the images.
During the measurement process of integrated depth doses, there was initially some concern regarding incomplete charge collection by the 8 cm diameter PTW Bragg peak chamber. 1,2 Saini et al. 2 presented a quantitation of charge loss during IDD measurements for their system but noted TPS performance was clinically acceptable under most conditions. Given the smaller in-air spot sigma of our system, we expected and observed similar results. With the exception of specific instances involving a range shifter discussed below, our TPS has performed as expected during all validation tests.
The calibration curve of Hounsfield units to physical density was tested against five patient CT scans as discussed previously. The variation observed in mean physical density in adipose, muscle, and cortical bone was less than 3% compared to ICRU 49 values as demonstrated in Table 2 . As detailed previously, relative linear stopping power (RLSP) comparisons were performed for the five patient scans and tissues as well as the Gammex tissue characterization plugs. RayStation compared well against both the independent stoichiometric calibration, the method presented by Fippel and T A B L E 2 Physical density and relative linear stopping power comparisons for three tissue types sampled from five patient CT datasets. with lung dose calculations performed by RayStation was minimized after our institution successfully met all criteria of the IROC anthropomorphic proton lung phantom evaluation (see below/ Table 4 ).
Independent assessments of our entire proton treatment process were performed prior to the treatment of the first patient. Our process met all criteria of the IROC absolute dose TLD checks and passed a comprehensive review by a group of proton physicists.
Within 6 months, our facility successfully met all criteria of the IROC anthropomorphic prostate, head and lung phantom tests, as demonstrated in Table 4 .
We note several areas where further development of either the 
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